A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Chronic Neuropathic Pain

NCT00214955 Phase 3 COMPLETED

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for the Management of Breakthrough Pain in Opioid-Tolerant Patients with Chronic Neuropathic Pain

Details

Lead sponsor	Cephalon
Phase	Phase 3
Status	COMPLETED
Enrolment	120
Start date	2005-09

Conditions

• Chronic Neuropathic Pain

Interventions

• ORAVESCENT Fentanyl Citrate

Countries

United States